23 completed, 5 unknown, 3 withdrawn, 2 terminated. 34 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Completed 23, Unknown 5, Withdrawn 3, Terminated 2, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Interferon beta-1a: new trials by email Literature Review of Interferon beta-1a trials Research Report on Interferon beta-1a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Early Interferon-beta Treatment for West-Nile Virus Infection Rebif 44 MCG Per 0.5 ML Prefilled Syringe, Saline - West Nile Virus, West Nile Fever Encephalitis | Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 100 | 2024-07-14 | 2024-07-23 |
| Nivolumab in Children and Adults With Nasopharyngeal Carcinoma Nivolumab, Cisplatin, 5-Fluorouracil - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 2 | Recruiting | German Society for Pediatric Oncology and Hematology GPOH gGmbH | 57 | 2023-01-10 | 2024-05-16 |
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients MetFORMIN 1000 Mg Oral Tablet, Interferon beta-1a - Multiple Sclerosis | Phase 2 | Unknown | German University in Cairo | 80 | 2022-02-01 | 2023-03-20 |
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Biogen | 2021-06-30 | 2023-06-01 | |
| the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19 High dose Interferon-beta 1a, Lopinavir/Ritonavir, Low dose Interferon-beta 1a - Covid19 | Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 100 | 2020-08-20 | 2020-08-20 |
| An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial Hydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A - COVID-19 | Phase 2 | Completed | Shahid Beheshti University of Medical Sciences | 60 | 2020-04-09 | 2020-05-05 |
| A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza Interferon Beta-1A, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | Synairgen Research Ltd. | 122 | 2018-01-29 | 2023-01-04 |
| Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis BCD-054 180 mcg, Avonex®, BCD-054 240 mcg - Multiple Sclerosis, Relapsing-Remitting | Phase 2 / Phase 3 | Completed | Biocad | 399 | 2017-08-10 | 2021-09-08 |
| Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA Interferon Beta-1A, Placebo - Preventive Medicine, Multi Organ Failure | Phase 2 | Terminated | Faron Pharmaceuticals Ltd | 40 | 2017-02-18 | 2021-01-14 |
| Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis BCD-033 (interferon beta 1a), Rebif (interferon beta 1a), Placebo - Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Biocad | 163 | 2015-02-12 | 2023-02-17 |
| Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex BIIB033, Placebo, Avonex - Multiple Sclerosis | Phase 2 | Completed | Biogen | 419 | 2013-08-01 | 2017-05-03 |
| Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a IFN beta 1a 44 mcg TIW, Curcumin, Placebo - Multiple Sclerosis | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 80 | 2012-04-30 | 2019-01-22 |
| Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide teriflunomide, Interferon-β-1, Influenza vaccine - Multiple Sclerosis | Phase 2 | Completed | Sanofi | 128 | 2011-09-01 | 2016-02-18 |
| Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment VigantOL oil plus interferon beta-1a (Rebif), Placebo plus interferon beta-1a (Rebif), Interferon beta-1a (Rebif®) alone - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 260 | 2011-02-01 | 2016-11-28 |
| Comparing Efficacy and Safety of Inhaled SNG001 to Placebo Interferon beta 1a, Placebo - Asthma | Phase 2 | Completed | Synairgen Research Ltd. | 300 | 2010-03-01 | 2012-02-13 |
| Treatment Interruption of Natalizumab natalizumab, interferon beta 1-a, methylprednisolone - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Biogen | 175 | 2010-03-01 | 2013-09-19 |
| A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly Cholecalciferol (Vitamin D3), Placebo, Rebif - Multiple Sclerosis | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 129 | 2009-11-01 | 2017-12-14 |
| A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis Placebo, Ocrelizumab, Avonex - Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Completed | Genentech, Inc. | 220 | 2008-07-17 | 2024-12-31 |
| A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis BG9418 (Interferon beta-1a), Placebo - Active Ulcerative Colitis | Phase 2 | Completed | Biogen | 123 | 2008-05-01 | 2014-08-13 |
Showing 20 of 34. Sign in to see all of them.
Multiple Sclerosis (15) · Multiple Sclerosis, Relapsing-Remitting (8) · COVID-19 (2) · Colitis, Ulcerative (2) · Recurrence (2) · Alzheimer Disease (1) · Asthma (1) · Burkitt Lymphoma (1) · Crohn Disease (1) · Dementia (1) · Disease Progression (1) · Encephalitis (1) · Inflammation (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1)
Biogen (6) · Merck KGaA, Darmstadt, Germany (4) · Sanofi (3) · Biocad (2) · EMD Serono (2) · Shahid Beheshti University of Medical Sciences (2) · Synairgen Research Ltd. (2) · EMD Serono Research & Development Institute, Inc. (1) · Faron Pharmaceuticals Ltd (1) · Fred Hutchinson Cancer Center (1) · Genentech, Inc. (1) · Genzyme, a Sanofi Company (1) · German Society for Pediatric Oncology and Hematology GPOH gGmbH (1) · German University in Cairo (1) · Multiple Sclerosis Institute (1)
United States (14) · Italy (10) · Germany (9) · United Kingdom (9) · Russia (8) · Canada (7) · Spain (6) · Switzerland (4) · Austria (3) · Czechia (3) · France (3) · Netherlands (3) · Poland (3) · Denmark (2) · Estonia (2)
Claudia Pena Rossi, M.D. (2) · Allan Ropper, MD (1) · Andrea Paolillo, MD, PhD (1) · Behnam Rahimi, M.D (1) · Carlo Pozzilli, MD (1) · Emmanuelle Waubant, MD PhD (1) · Emmanuelle Waubant, MD, PhD (1) · Fabiana Marinelli, MD (1) · Firouze Hatami, M.D (1) · Fred Lublin, MD, PhD (1)
PMID 22622860, PMID 15714427, PMID 18946064, PMID 19145731, PMID 19302707, PMID 20659956, PMID 21397567, PMID 21960587, PMID 22047971, PMID 22442431, PMID 23459567, PMID 23851964, PMID 24170099, PMID 24937476, PMID 25929276, PMID 26049148, PMID 26396053, PMID 27000249, PMID 27995531, PMID 28148632, PMID 28607708, PMID 30027104, PMID 30144037, PMID 31285147, PMID 31454777, PMID 31594857, PMID 32447743, PMID 32493468, PMID 33106183, PMID 33763778, PMID 33850184, PMID 34224994, PMID 34583214, PMID 34882037, PMID 35115574, PMID 36780676, PMID 37272540, PMID 38070031, PMID 38648580
2009 (1), 2014 (1), 2017 (1), 2019 (1)